NO20015931L - Farmasöytiske formuleringer og fremgangsmåter som omfatter intranasal morfin - Google Patents

Farmasöytiske formuleringer og fremgangsmåter som omfatter intranasal morfin

Info

Publication number
NO20015931L
NO20015931L NO20015931A NO20015931A NO20015931L NO 20015931 L NO20015931 L NO 20015931L NO 20015931 A NO20015931 A NO 20015931A NO 20015931 A NO20015931 A NO 20015931A NO 20015931 L NO20015931 L NO 20015931L
Authority
NO
Norway
Prior art keywords
morphine
methods
pharmaceutically acceptable
acceptable salt
pharmaceutical formulations
Prior art date
Application number
NO20015931A
Other languages
English (en)
Norwegian (no)
Other versions
NO20015931D0 (no
Inventor
Charanjit R Behl
Raja G Achari
Jorge C Demeireles
Ramneik Dua
Vincent D Romeo
Anthony P Sileno
Original Assignee
Nastech Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nastech Pharm Co filed Critical Nastech Pharm Co
Publication of NO20015931D0 publication Critical patent/NO20015931D0/no
Publication of NO20015931L publication Critical patent/NO20015931L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20015931A 1999-06-16 2001-12-04 Farmasöytiske formuleringer og fremgangsmåter som omfatter intranasal morfin NO20015931L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33453799A 1999-06-16 1999-06-16
PCT/US2000/014157 WO2000076506A1 (fr) 1999-06-16 2000-05-23 Formulations pharmaceutiques et procedes comprenant de la morphine s'administrant par voie intra-nasale

Publications (2)

Publication Number Publication Date
NO20015931D0 NO20015931D0 (no) 2001-12-04
NO20015931L true NO20015931L (no) 2002-02-08

Family

ID=23307687

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015931A NO20015931L (no) 1999-06-16 2001-12-04 Farmasöytiske formuleringer og fremgangsmåter som omfatter intranasal morfin

Country Status (30)

Country Link
US (1) US6677346B1 (fr)
EP (2) EP1183027A4 (fr)
JP (1) JP2003501467A (fr)
KR (1) KR20020016831A (fr)
AU (1) AU774175B2 (fr)
BG (1) BG106221A (fr)
BR (1) BR0012082A (fr)
CA (1) CA2374877C (fr)
CZ (1) CZ20014399A3 (fr)
DE (1) DE10084709T1 (fr)
DK (1) DK200101859A (fr)
EE (1) EE200100677A (fr)
ES (1) ES2197792B1 (fr)
FI (1) FI20012462A7 (fr)
GB (1) GB2367005A (fr)
HR (1) HRP20010926A2 (fr)
HU (1) HUP0201856A3 (fr)
IS (1) IS6202A (fr)
LT (1) LT4976B (fr)
LU (1) LU90859B1 (fr)
LV (1) LV12859B (fr)
MX (1) MXPA01012879A (fr)
NO (1) NO20015931L (fr)
NZ (1) NZ515783A (fr)
PL (1) PL352556A1 (fr)
SE (1) SE0104203L (fr)
SI (1) SI20850A (fr)
SK (1) SK18172001A3 (fr)
TR (1) TR200103613T2 (fr)
WO (1) WO2000076506A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9924797D0 (en) 1999-10-20 1999-12-22 West Pharm Serv Drug Res Ltd Compound
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US6572849B2 (en) * 2000-09-20 2003-06-03 Lee Shahinian, Jr. Self-preserved antibacterial nasal, inhalable, and topical ophthalmic preparations and medications
EP1418862A4 (fr) * 2001-06-29 2010-06-09 Leon J Lewandowski Therapie de sevrage individualisee en cas de dependance
GB0210264D0 (en) * 2002-05-03 2002-06-12 Arakis Ltd The treatment of pain and migraine headache
US20040102476A1 (en) * 2002-11-25 2004-05-27 Chan Tai Wah High concentration formulations of opioids and opioid derivatives
US20050175679A1 (en) * 2004-02-10 2005-08-11 Michael Moshman Controlled release formulations
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
PL2486942T3 (pl) 2004-11-24 2019-05-31 Meda Pharmaceuticals Inc Kompozycje zawierające azelastynę oraz sposoby ich stosowania
US9415034B2 (en) * 2005-01-05 2016-08-16 National Defense Medical Center Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2B (UGT2B)
ES2277743B2 (es) 2005-06-02 2008-12-16 Universidade De Santiago De Compostela Nanoparticulas que comprenden quitosano y ciclodextrina.
JP5276982B2 (ja) 2005-08-26 2013-08-28 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ オキシトシンの投与による頭痛の処置のための方法
US20070212307A1 (en) * 2006-02-10 2007-09-13 Daniel Wermeling Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
AU2007338210B2 (en) * 2006-12-22 2013-01-31 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Gel useful for the delivery of ophthalmic drugs
GB2477545B (en) * 2010-02-05 2011-12-21 Special Products Ltd A liquid morphine composition for buccal administration
HRP20180233T1 (hr) 2011-05-13 2018-06-01 Euro-Celtique S.A. Intranazalni farmaceutski oblici doziranja koji sadrže nalokson
US20150231130A1 (en) 2012-07-26 2015-08-20 Wockhardt Limited Pharmaceutical composition comprising diamorphine for intranasal administration
WO2015095389A1 (fr) * 2013-12-18 2015-06-25 Aegis Therapeutics, Llc Compositions pour administration de médicaments
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
PL3242676T3 (pl) 2015-01-07 2024-07-15 Tonix Pharma Limited Preparaty oksytocyny zawierające magnez i sposoby ich stosowania
HRP20250215T1 (hr) 2016-04-12 2025-06-20 Tonix Pharma Limited Formulacije oksitocina koje sadrže magnezij i postupci upotrebe
EP3528797A1 (fr) * 2016-10-21 2019-08-28 Somniferum Labs LLC Compositions, méthodes et kits pour l'administration par inhalation sûre d'opioïdes ciblés pour le traitement de la douleur et de la dépendance
MA50394A (fr) * 2017-10-20 2021-04-28 Chiesi Farm Spa Formulations pharmaceutiques comprenant un agoniste de récepteur d'opioïde en tant que substances actives, leurs procédés de fabrication et leurs utilisations thérapeutiques
JP6941224B2 (ja) 2018-02-06 2021-09-29 イージス セラピューティクス，エルエルシー 疾患の処置のための鼻腔内エピネフリン製剤及び方法
CN115804754A (zh) * 2022-12-16 2023-03-17 广州新济药业科技有限公司 吗啡鼻喷剂及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4464376A (en) 1982-07-22 1984-08-07 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
US5202128A (en) 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
DE69434304T2 (de) * 1993-03-26 2005-12-29 Merkus, Franciscus Wilhelmus H.M. Pharmazeutische Zusammensetzungen zur intranasalen Verabreichung von Dihydroergotamin
GB9426102D0 (en) 1994-12-23 1995-02-22 Merck Sharp & Dohme Pharmacuetical compositions
CA2266898A1 (fr) * 1996-09-27 1998-04-02 Nastech Pharmaceutical Co., Inc. Formulations intranasales pour favoriser le sommeil et leur procede d'utilisation

Also Published As

Publication number Publication date
EE200100677A (et) 2003-02-17
US6677346B1 (en) 2004-01-13
CA2374877A1 (fr) 2000-12-21
MXPA01012879A (es) 2003-06-24
PL352556A1 (en) 2003-08-25
HUP0201856A3 (en) 2004-12-28
GB2367005A (en) 2002-03-27
LT4976B (lt) 2002-12-30
GB0128383D0 (en) 2002-01-16
AU5156100A (en) 2001-01-02
SE0104203D0 (sv) 2001-12-14
CZ20014399A3 (cs) 2002-06-12
EP1183027A1 (fr) 2002-03-06
DK200101859A (da) 2001-12-12
HUP0201856A1 (en) 2002-09-28
EP1419774A1 (fr) 2004-05-19
DE10084709T1 (de) 2002-09-26
SK18172001A3 (sk) 2002-07-02
WO2000076506A1 (fr) 2000-12-21
SI20850A (sl) 2002-10-31
LU90859B1 (en) 2002-01-24
LV12859B (en) 2002-12-20
IS6202A (is) 2001-12-14
NZ515783A (en) 2004-05-28
NO20015931D0 (no) 2001-12-04
ES2197792A1 (es) 2004-01-01
KR20020016831A (ko) 2002-03-06
LT2001119A (en) 2002-07-25
AU774175B2 (en) 2004-06-17
FI20012462L (fi) 2002-01-16
BG106221A (bg) 2002-08-30
ES2197792B1 (es) 2005-05-01
JP2003501467A (ja) 2003-01-14
BR0012082A (pt) 2002-05-07
SE0104203L (sv) 2001-12-14
TR200103613T2 (tr) 2004-08-23
HRP20010926A2 (en) 2003-04-30
CA2374877C (fr) 2004-04-13
EP1183027A4 (fr) 2003-02-05
FI20012462A7 (fi) 2002-01-16

Similar Documents

Publication Publication Date Title
GB2367005A (en) Pharmaceutical formulations and methods comprising intranasal morphine
WO2002042462A3 (fr) Agents therapeutiques et methodes d'utilisation de ces agents therapeutiques pour traiter une maladie amyloidogenique
WO2000021515A3 (fr) Codeine intra-nasale permettant d'eliminer rapidement la toux et de soulager rapidement la douleur
NO20040968L (no) Opioidagonistpreparater med frigjorbar og sekvestrert antagonist
ATE247461T1 (de) Formulierung zur intranasalen verabreichung
EP1033998A4 (fr) Procedes de suppression des modifications liees aux beta-amyloides dans la maladie d'alzheimer
AU3846901A (en) Oral, nasal and pulmonary dosage formualtions of copolymer 1
MXPA01012882A (es) Composiciones y metodos que comprenden gluconato de morfina.
DE69824313D1 (de) Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
ATE311928T1 (de) (-)-pseudoephedrin als sympathomimetisches arzneimittel
NO20042758L (no) Fremgangsmate for behandling av en pasient som krever analgesi.
TW200633694A (en) Composition and method for treating asthma
BR0011880A (pt) Método para o tratamento de condições co-mórbidas associadas com obesidade, composto, produto, uso de um composto, e, composição farmacêutica
TW200700075A (en) Roflumilast and integrin inhibitor combination and method of treatment
MY131159A (en) New pharmaceutical compositions containing epinastine and pseudoephedrine
SE0002354D0 (sv) New formulation
GB2635282A8 (en) An oral liquid formulation of apixaban
MY133957A (en) "compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor"
AU2001295839A1 (en) Use of agents active against candida in the treatment of disorders of the oral and intestinal mucosa
EE200300555A (et) Morfiini sisaldav farmatseutiline preparaat ninasiseseks manustamiseks ning meetod valuvaigistava või tuimastava reaktsiooni esilekutsumiseks imetajal
WO2001035946A3 (fr) Administration intranasale de raloxifene et de tamoxifene
EP1095655A3 (fr) Recepteurs antagonistes NK-1 et eletriptan pour le traitement de la migraine

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application